SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the upcoming presentation of data from recent Phase 2 clinical studies of Alvocidib at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30th thru June 3rd.
Details of the oral and poster presentations are as follows:
Abstract: #7087
Poster: #372
Session Title: Leukemia,
Myelodysplasia and Transplantation
Presenter: William E.
Pierceall, PhD
Title: Distinct biomarkers as prognostic in
chronic lymphocytic leukemia patients treated with alvocidib and
lenalidomide as single agents or combination regimens thereof
Date:
Monday, June 2, 2014; 1:15 p.m.-5:00 p.m. CDT
Location: McCormick
Place, S Hall A2, Chicago
Abstract: #7002
Session Title: Leukemia,
Myelodysplasia and Transplantation
Presenter: Joshua F.
Zeidner, MD
Title: Randomized multicenter phase II trial of
timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and
mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute
myeloid leukemia (AML)
Date: Tuesday, June 3, 2014; 9:45
a.m.-9:57 a.m. CDT
Location: McCormick Place, E354a
About Alvocidib
Alvocidib is a potent cyclin-dependent kinase (CDK) small molecule inhibitor in development as a frontline combination therapy for acute myeloid leukemia and relapsed/refractory chronic lymphocytic leukemia and other hematologic disorders. CDKs are regulatory proteins and enzymes that are critical to a cell's ability to replicate as well as critical regulators of gene expression. Because of the key role CDK deregulation plays in runaway cell division and growth, CDK inhibitors remain an attractive target for the treatment of various cancers.
Alvocidib has been evaluated in multiple Phase 2 clinical trials involving approximately 400 patients with both relapsed/refractory or frontline, previously untreated intermediate and high-risk AML. In these trials, Alvocidib has been evaluated as a single agent as well as in combination with approved agents including cytarabine and mitozantrone. Alvocidib is currently being investigated in a Phase 2 study for the treatment of intermediate and high-risk AML in combination with standard of care agents.
About Acute Myeloid Leukemia
About 18,000 new cases of AML are expected to be diagnosed this year in the United States, according to estimates from the American Cancer Society. AML is a very rapidly growing cancer of the bone marrow and the myeloid lineage of blood cells. It is the most common acute leukemia in adults and accounts for approximately one-third of all adult leukemias in the United States and Europe. Typically, the prognosis of AML patients is categorized as low, intermediate or high-risk based on a profile of clinical, cytogenetic and molecular features which are used to assign risk of a poor outcome for treatment. Intermediate and high-risk AML constitute a significant percentage of all cases of adult AML. For these patients, treatment options are limited and their prognosis is usually poor. Alvocidib is currently being investigated in this specific patient population.
About Tolero
Tolero Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to alleviating human suffering through the discovery and development of novel therapeutics to treat cancer and other serious human diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat acute and chronic leukemias and anemia. For more information about Tolero please visit our website at www.toleropharma.com.